Publications by authors named "Agnieszka Roman"
Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.
Clin Exp Med
January 2025
Immune checkpoint inhibitors have improved the treatment of metastatic renal cell carcinoma (RCC), with the combination of nivolumab (NIVO) and ipilimumab (IPI) showing promising results. However, not all patients benefit from these therapies, emphasizing the need for reliable, easily assessable biomarkers. This multicenter study involved 116 advanced RCC patients treated with NIVO + IPI across nine oncology centers in Poland.
View Article and Find Full Text PDFBackground: Immune checkpoint inhibitors (ICIs) have been employed in the adjuvant and metastatic setting of renal cell carcinoma (RCC) treatment. Among ICIs, combined immunotherapy has the highest risk for immune-related adverse events (irAEs). We aimed to document the incidence of irAEs in RCC patients treated with nivolumab and ipilimumab as data from the European population remain limited.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the effectiveness and safety of immunotherapy using checkpoint inhibitors for older patients (70 years and above) diagnosed with metastatic melanoma, addressing a gap in knowledge for this demographic.
- A total of 82 patients aged 70 and older were analyzed, revealing comparable median progression-free survival (PFS) and overall survival (OS) rates between older and younger patients, with a 2-year OS of 27% for the older group.
- Results indicate that despite the presence of co-morbidities, older patients can tolerate immunotherapy similarly to younger patients, suggesting that age should not prevent them from receiving this treatment.